Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | cDCs | 0.486151 | 7.70e-12 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | cDCs | 0.310651 | 6.85e-06 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Mono/Macro | 0.273762 | 2.49e-23 |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | cDCs | 0.277338 | 4.78e-04 |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Mono/Macro | 0.256427 | 5.61e-27 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | -0.321584 | 2.72e-08 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mono/Macro | -0.323852 | 5.59e-04 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | pre | Mono/Macro | 0.323274 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | Mono/Macro | -0.347592 | 0.00e+00 |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive non-small cell lung cancer (NSCLC) | Targeted therapy | ceritinib | NA | Malignant cells | -0.78641 | 0.00e+00 |
GSE149214 | PC9 cell line | Cell line | Lung cancer | EGFR-mutated non-small cell lung cancer (NSCLC) | Targeted therapy | erlotinib | NA | Malignant cells | 0.287744 | 8.30e-26 |
Gene symbol | motif | TF_highConf |
NCF2 | metacluster_22.12 | NFE2; NFE2L1 (directAnnotation). |
NCF2 | kznf__ZNF90_Imbeault2017_RP_RCADE | ZNF90 (directAnnotation). |
NCF2 | metacluster_30.4 | BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation). |
NCF2 | transfac_pro__M06304 | ZNF260 (directAnnotation). |
NCF2 | homer__ATTGCGCAAC_CEBP | CEBPB (inferredBy_Orthology). |
NCF2 | taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNNTTRCGYAAN_CAP | CEBPB; GCM1 (directAnnotation). |
NCF2 | taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNTTRCGYAAN_CAP | CEBPB; GCM1 (directAnnotation). |
NCF2 | dbtfbs__ZNF121_HEK293_ENCSR224QDY_merged_N3 | ZNF121 (directAnnotation). |
NCF2 | metacluster_46.5 | HLF; TEF (directAnnotation). |
NCF2 | transfac_pro__M04722 | SPI1 (directAnnotation). |
NCF2 | metacluster_46.4 | CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; DBP; DBP; EP300; GATAD2A; HES2 (directAnnotation). CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; HLF; HLF (inferredBy_Orthology). |
NCF2 | transfac_pro__M06092 | ZNF28 (directAnnotation). |
NCF2 | transfac_pro__M05743 | ZNF57 (directAnnotation). |
NCF2 | metacluster_93.2 | ZFP41; ZFP41 (directAnnotation). |
NCF2 | transfac_pro__M06383 | ZNF629 (inferredBy_Orthology). |
NCF2 | hdpi__FOSL1 | FOSL1 (directAnnotation). |
NCF2 | cisbp__M01815 | CEBPE (inferredBy_Orthology). |
NCF2 | jaspar__MA1954.1 | FOXO1 (directAnnotation). |
NCF2 | metacluster_167.7 | IRF8 (inferredBy_Orthology). |
NCF2 | taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr | CEBPD; ETV2 (directAnnotation). |
NCF2 | taipale_tf_pairs__FLI1_CEBPB_RNCGGANNTTGCGCAAN_CAP | CEBPB; FLI1 (directAnnotation). |
NCF2 | metacluster_22.29 | NFE2 (directAnnotation). |
NCF2 | metacluster_22.25 | NFE2L2 (directAnnotation). |
NCF2 | taipale_tf_pairs__POU2F1_DLX2_TGMATATKCANNNNNTAATKR_CAP_repr | DLX2; POU2F1 (directAnnotation). |
NCF2 | jaspar__MA1946.1 | FOXI1 (directAnnotation). |
NCF2 | jaspar__MA1955.1 | FOXO1 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |